Psychopharmacology of MDMA (Ecstasy)

Psychiatric Annals

Volumn 31, Issue 11, 2001, Pages 675-681

  Gold, Mark S ^a   Tabrah, Haleh ^a   Frost Pineda, Kimberly ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23044530561     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20011101-09     Document Type: Article

References (29)

1. Miller NS, Gold MS. LSD and ecstasy: pharmacology, phenomenology, and treatment. Psychiatric Annals. 1994; 24:131-133.
2. Gold MS, McKewen M. Trends in hallucinogenic drug use: LSD, "ecstasy," and the rave phenomenon. Directions in Psychiatry. 1995;15:1-7.
3. McDowell DM, Kleber HD. MDMA: its history and pharmacology. Psychiatric Annals. 1994;24:127-130.
4. Partnership for a Drug-Free America. The 2000 Partnership Attitude Tracking Study (PATS): Teens Continuing to Turn Away From Marijuana, But Small, Increasing Number Take to Ecstasy. New York: Partnership for a Drug-Free America; 2001. Available at www.drugfreeamerica.org.
5. Office of Applied Studies, Substance Abuse and Mental Health Administration. Drug Abuse Warning Network Detailed Emergency Department (ED) Tables, 1999. Washington, DC: Substance Abuse and Mental Health Administration; 1999. Available at www.samhsa.gov/ statistics.
6. De la Torre R, Farre M, Ortuno J, et al. Non-linear pharmacokinetics of MDMA ("ecstasy") in humans. Br J Clin Pharmacol. 2000;49:104-109.
7. Mas M, Farre M, De la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136-145.
8. McCann UD, Slate SO, Ricaurte GA. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"). Drug Saf. 1996;15:107-115.
9. Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut. 1996;38:454-458.
10. Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol. 1998; 29:394-397.
11. Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19:157-164.
12. Rattray M. Towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem. 1991;12:77-87.
13. Parrott AC, Sisk E, Turner JJ. Psychobiological problems in heavy "ecstasy" (MDMA) polydrug users. Drug Alcohol Depend. 2000;60:105-110.
14. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. Cognitive performance in (+-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology. 1999;143:417-425.
15. Ricaurte GA, Yuan J, McCann UD. (+-)3,4-methylenedioxymethamphetamine ("ecstasy")-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology. 2000;42:5-10.
16. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (±) 3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci. 1999;19:5096-5107.
17. Scheffel U, Szabo Z, Mathews WB, et al. In vivo detection of short- and long-term MDMA neurotoxicity: a positron emission tomography study in the living baboon brain. Synapse. 1998;29:183-192.
18. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet. 1998;352:1433-1437.
19. Reneman L, Booij J, Schmand B, van den Brink W, Gunning B. Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology (Berl). 2000;148:322-324.
20. Chang L, Grob CS, Ernst T, et al. Effect of ecstasy [3,4-methylenedioxymethamphetamine] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res. 2000;98:15-28.
21. Reneman L, Habraken JB, Majoie CB, Booij J, den Heeten GJ. MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. AJNR Am J Neuroradiol. 2000;21:1001-1007.
22. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology. 2000;23:396-404.
23. Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA (Ecstasy) after haloperiodol pretreatment in healthy humans. Eur Neuropsychopharmacol. 2000;10:289-295.
24. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000;22:513-521.
25. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS. Striatal serotonin is depleted in brain of human MDMA (ecstasy) user. Neurology. 2000;55:294-296.
26. Rodgers J. Cognitive performance amongst recreational users of "ecstasy." Psychopharmacology (Berl). 2000;151:19-24.
27. Reuters Health Information. Young Women at Greatest Risk From Ecstasy Drug. New York: Reuters; 2000. Available at www.reutershealth.com.
28. Shankaran M, Yamamoto BK, Gudelisky GA. Ascorbic acid prevents MDMA-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of 5-HT. Society for Neuroscience Abstracts. 2000;26(Part 2):869.16.
29. Xie T, McCann UD, Kim S, Yuan J, Ricaurte GA. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2000;20:7838-7845.